A Hospital Based Survey on Lung Cancer Related-pain in Northern China

Lung Cancer Clinical Trial

Official title:

Clinical Characteristics, Evaluation and Management of Lung Cancer Related-pain in Northern China: a Hospital-based Cross-sectional Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03189277
• Other study ID #: CH-PT-002
• Status: Not yet recruiting
• Phase: N/A
• First received: June 14, 2017
• Last updated: June 15, 2017
• Start date: June 2017
• Est. completion date: September 2017

Study information

• Verified date: June 2017
• Source: Chinese Academy of Medical Sciences
• Contact: Yuankai Shi, MD
• Phone: 86-10-87788293
• Email: syuankaipumc[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This cross-sectional study, utilizing two sets of questionaire designed for patients and physicians respectively, aims at the epidemiology, the clinical features, and the current status of evaluation and management of lung cancer related pain in 20 participating hospitals in Northern China.

Description:

Lung malignancies have become the most common cause of mortality among patients with cancer in China. A significant proportion of lung cancer patients suffer from cancer related pain, however few studies have reported the prevalence and clinical features of such pain, especially in China.

This study is a cross-sectional survey in 20 hospitals in Northern China. We designed two separate series of questions to be answered by patients and cancer management professionals. In the patient questionaire, we collect information on the prevalence, location, intensity, impact on life of lung cancer related pain. Questions on how doctors evaluate and manage the pain are included in both the patients' and physicians' surveys. In the doctors' questionaire, we also assess current situation of cancer pain educational programs attended in medical schools and post graduation through related questions.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 2000
• Est. completion date: September 2017
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. The patient questionaire

• All patients (outpatient and inpatient) diagnosed with lung cancer visiting the participating hospitals on the designated day of investigation

• Informed consent must be obtained from the participating patients

2. The physician questionaire

• All physicians who receive lung cancer patients (outpatient and inpatient) in the participating hospitals on the designated day of investigation

Related Conditions & MeSH terms

• Cancer Pain
• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (20)

Lead Sponsor

Collaborator

Chinese Academy of Medical Sciences

307 Hospital of PLA, 309th Hospital of Chinese People's Liberation Army, Beijing Cancer Hospital, Beijing Chao Yang Hospital, Beijing Chest Hospital, Chinese PLA General Hospital, Daxing Hospital Beijing, Hebei Medical University Fourth Hospital, Henan Cancer Hospital, Inner Mongolia People's Hospital, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Peking University Third Hospital Yanqing Hospital, Shanxi Province Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Hospital of Shunyi District Beijing, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University General Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of cancer-related pain in lung cancer patients in 20 hospitals in northern China	the proportion of self-reported pain related to cancer affecting the enrolled lung cancer patients over the past 24 hours	24 hours